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data source to identify patients with AS and their insurance claim records in 2013 
for in-patient care and out-patient care. The identified patients were stratified by 
AS-related medications for the comparisons on drug costs and non-drug medical 
costs. Generalized linear model (GLM) was conducted to assess the impact of the 
classified medications on on-drug medical costs after full adjustment of patient 
baseline characteristics including demography, AS-related to complications, and 
comorbidities. Results: Among the identified 1299 patients with diagnosed AS, the 
AS-related medications included nonsteroidal anti-inflammatory drugs (NSAIDs) 
(n= 234), immunosuppressant (n= 146), combination of NSAID and immunosuppres-
sant (n= 626), biologics (n= 60), and Chinese medications (n= 233). The total medical 
costs associated with AE-related treatments ranged from RMB 4,565 for Chinese 
medication to RMB 24,585 for biologics treatment (1 RMB = 0.16 US$). However, bio-
logics treatment and the combination treatment of NSAID and immunosuppressant 
had similar non-drug medical costs (RMB 7,039 versus RMB 7,450, p= 0.164). GLM 
regression analysis further confirmed highly comparable non-drug medical costs 
associated with biologics (coefficient: 0.0639, p = 0.741) relative to the combination 
treatment of NSAID and immunosuppressant. ConClusions: Among publically 
insured Chinese patients with AS, biologics treatments were associated with highly 
comparable non-drug medical costs as the combination treatment of NSAID and 
immunosuppressant. This finding suggests that biologics may effectively control 
health resource utilization through their superior treatment effects.
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objeCtives: The aim of this study was to assess the indirect costs caused by absen-
teeism associated with psoriatic and enteropathic arthropathies from the perspective 
of the Social Insurance Institution (ZUS) in Poland. Methods: The estimates were 
based on data from the year 2013 concerning sick leave and the amount of short-
term disability, the sufferers of which claim rehabilitation benefit, and the amount of 
long-term disability (permanent or fixed time), the sufferers of which claim disability 
pension. Costs calculated taking into account Gross Domestic Product (GDP) per capita 
equaled € 10 278, Gross Value Added (GVA) per worker equaled € 24 680 and Gross 
Income (GI) per worker equaled € 7 339 were presented in 2013 prices. Results: Total 
indirect costs of psoriatic and enteropathic arthropathies in the year 2013 calculated 
using GDP per capita, GVA and GI per worker in Poland were € 7 341 217, € 17 628 441 
and € 5 242 346, respectively. The highest component of indirect costs was permanent 
long-term disability (43%). Fixed period long-term disability and short-term disability 
costs constitute 20% and 9% of total indirect costs, respectively. In 2013 Poland’s Social 
Insurance Institution database reported 2 100 patients that had 4 922 sick leave epi-
sodes, 180 short-term disability episodes and 80 long-term disability episodes. Indirect 
costs per patient associated with sick leave were € 1 030, € 2 474 and € 736 calculated 
using GDP, GVA and GI, respectively. Indirect costs per patient associated with short-
term disability were € 298, € 715 and € 212 respectively and associated with long-term 
disability were as high as € 2 168, € 5 206 and € 1 548, respectively. ConClusions: 
Psoriatic and enteropathic arthropathies in Poland generated high indirect costs. The 
main component was permanent long-term disability; short-term disability gener-
ated lower costs of lost productivity. The highest cost per patient was generated by 
permanent long-term disability.
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objeCtives: To estimate the direct cost of Del5q MDS from the perspective of 
the public healthcare system in Mexico Methods: We evaluated the amount of 
resources utilized by patients with Del5q MDS from an expert panel of eight hema-
tologist through the Delphi technique. Consensus was reached after two expert 
panel rounds and patterns of use were analyzed statistically. Unit costs of resources 
were extracted from institutional catalogues and annual cost estimations were 
performed for different health states. All values were expressed in US dollars of 
2015 Results: From the consensus of panel experts we found that management 
of patients with Del5q MDS at Mexican public healthcare institutions consisted 
of best supportive care with red blood cell (RBC) transfusions and erythropoiesis-
stimulating agents, and since these patients are RBC-transfusion dependent, they 
receive 33 units of RBC per year resulting in a cost of US$5,265.60. Iron overload is 
the main complication of transfusion dependency resulting in an annual cost of 
US$1,782.11 attributable to congestive heart failure. Other resources used to the 
treatment of the disease are drugs, labs, and visits that contribute to the total annual 
cost of US$30,647.78 per patient ConClusions: MDS patients with 5q deletion 
impose a high economic burden to the public healthcare system in Mexico, although 
the incidence is lower than other hematological malignancies
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Generalized Linear Models (log link, Gamma family) adjusting for gender, age, BMI, 
type of intervention, complications and comorbidites. Costs are expressed in Euro 
2013. Results: 280 patients (171 workers, 61%, and 109 no-workers including peo-
ple out of work, students, housewives and retirees, 39%) have been submitted to bar-
iatric surgery and followed up to 1 year after the intervention. The overall social cost, 
including costs of intervention and 1-year follow up, was € 11,310 (± € 3,778). Direct 
medical costs amounted to € 8,737 (± 2,527), representing the 77% of the overall cost, 
while direct non medical costs and indirect costs accounted for 13% and 10% (€ 1.497 
± € 1,928 and € 1,076 ± € 1,675). No working conditions had an incremental effect on 
direct non-medical costs of € 676 (95% CI: € 212-€ 1,140, p= 0.004). Working conditions 
increased indirect costs by € 1,384 (95% CI: € 1,002-€ 1,766, p= 0.000). ConClusions: 
Socio-economic determinant such as employment status of patient led to significant 
impacts on direct non medical costs and indirect costs of a patient submitted to 
bariatric surgery.
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objeCtives: The aim of this study was to assess the indirect costs caused by absen-
teeism associated with inflammatory bowel disease (IBD) - (Crohn’s disease – CD; 
and ulcerative colitis - UC) from the perspective of the Social Insurance Institution 
(ZUS) in Poland Methods: The estimates were based on data provided by ZUS 
referring to year 2013 and concerning absence from work due to the illness (sick 
leave), the amount of short-term disability, the sufferers of which claim rehabilita-
tion benefit, and the amount of permanent (or long-term) disability, the sufferers of 
which claim disability pension. Costs were calculated with Human Capital Approach 
methodology taking into account Gross Domestic Product (GDP) per capita equaled 
€ 10 278. Results: Total indirect costs of CD, UC in the year 2013 calculated using 
GDP per capita in Poland were € 7 817 156 and € 8 990 313, respectively. Total indirect 
costs of IBD in the year 2012 and 2013 in Poland were € 14 220 181 and € 16 807 469, 
respectively (an increase of nearly 15% because of substantial growth short-term 
disabilities). The highest component of indirect costs of IBD was sick leave (51%). 
Long and short-term disability costs constitute 39% (limited period – 19% and unlim-
ited period 20%) and 10% of total indirect costs of IBD, respectively. One sick leave of 
person with IBD generated the cost of lost productivity equal € 779 calculated using 
GDP per capita. Indirect cost of short-term disability for one entitlement to the ben-
efit of rehabilitation were € 7 314. Cost of one long-term benefit were much higher 
than short-term benefit and equaled for limited period € 36 714 and unlimited period 
€ 941. Total long-term disability costs amounted € 676 651. ConClusions: IBD in 
Poland generated high indirect costs. The main component was sick leave; reha-
bilitation benefit and disability pension generated lower costs of lost productivity.
PSY38
idioPAthiC PulmonArY fibroSiS: hoSPitAl diSeASe mAnAgement And 
ASSoCiAted CoStS
Cottin V1, Schmidt A2, Catella L2, Porte F3, Fernandez-Montoya C3, Le Lay K3, Bénard S2
1Centre Hospitalier Universitaire de Lyon, Groupement Hospitalier Est-Hôpital Louis Pradel, Bron, 
France, 2st[è]ve consultants, Oullins, France, 3Boehringer Ingelheim France, Paris, France
objeCtives: Idiopathic pulmonary fibrosis (IPF) is a chronic, fibro-proliferative 
and fatal lung disease. A study was conducted to describe the causes and main 
comorbidities of hospitalized patients and associated costs in France. Methods: 
A retrospective, observational study was set up using the French hospital discharge 
database (PMSI). Patients with a first hospitalization for IPF (ICD-10 code: J841) in 
2008 were identified and followed during a 5-year period. As J841 code includes 
other fibrotic pulmonary diseases, an algorithm for data extraction was defined, 
with exclusion of age< 50 and presence of a differential diagnosis in the follow-
ing year (connective disease or pneumoconiosis). Patient characteristics, first stay 
and occurrence of events of special interest were described as well as associated 
costs. Results: In 2008, 6,476 patients newly hospitalized for IPF were identified, 
with a mean age of 75.4±10.3 years, and 56% were men. The mean total cost of 
hospitalizations per patient for the 5-year follow-up period was € 15,532±15,973. 
Main cost drivers were the serious events related to the disease, specifically acute 
exacerbation (37% of patients, with a 10% in-hospital mortality rate and a cost of 
€ 4,091±4,429/event), cardiac events (48% of patients with a 14% in-hospital mortality 
rate and a cost of € 5,731±5,463/event), acute respiratory infections (44% of patients 
with a 18% in-hospital mortality rate and a cost of € 7,471±7,981/event) and arterial 
thrombosis (12% of patients with a 20% in-hospital mortality rate and a cost of 
€ 7,467±7,216/event). Finally, 11% of patients received palliative care with a mean 
cost for the last year of life of € 14,807±11,979 per deceased patient. ConClusions: 
This study is the first providing extensive data on hospital management for patients 
with IPF in France, demonstrating high burden and hospital cost, especially for acute 
respiratory deteriorations. These results could be used in economic evaluations for 
IPF patients in France.
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objeCtives: To estimate direct medical costs associated with ankylosing spondyli-
tis (AS) in publically insured Chinese patients. Methods: China Health Insurance 
Research Association (CHIRA) claim data containing patients randomly selected 
from publically insured urban residents and workers across China was used as the 
